edoc-vmtest

Items where Author is "Edan, G."

Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Date | Item Type | Refereed
Jump to: 2011 | 2008
Number of items: 4.

2011

Acaster, S. and Swinburn, P. and Wang, C. and Stemper, B. and Beckmann, K. and Knappertz, V. and Pohl, C. and Sandbrink, R. and Gondek, K. and Edan, G. and Kappos, L. and Freedman, M. and Hartung, H.-P. and Arnason, B. and Comi, G. and Filippi, M. and Jeffery, D. and O'Connor, P. and Cook, S. and Lloyd, A. J.. (2011) Can the functional assessment of multiple sclerosis adapt to changing needs? : a psychometric validation in patients with clinically isolated syndrome and early relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal, 17 (12). pp. 1504-1513.

Hartung, H.-P. and Freedman, M. S. and Polman, C. H. and Edan, G. and Kappos, L. and Miller, D. H. and Montalbán, X. and Barkhof, F. and Petkau, J. and White, R. and Sahajpal, V. and Knappertz, V. and Beckmann, K. and Lanius, V. and Sandbrink, R. and Pohl, C. and Benefit Study Group, . (2011) Interferon β-1b-neutralizing antibodies 5 years after clinically isolated syndrome. Neurology, Vol. 77, H. 9. pp. 835-843.

Kappos, L. and Bates, D. and Edan, G. and Eraksoy, M. and Garcia-Merino, A. and Grigoriadis, N. and Hartung, H. P. and Havrdova, E. and Hillert, J. and Hohlfeld, R. and Kremenchutzky, M. and Lyon-Caen, O. and Miller, A. and Pozzilli, C. and Ravnborg, M. and Saida, T. and Sindic, C. and Vass, K. and Clifford, D. B. and Hauser, S. and Major, E. O. and O'Connor, P. W. and Weiner, H. L. and Clanet, M. and Gold, R. and Hirsch, H. H. and Radu, E. W. and Sorensen, P. S. and King, J.. (2011) Natalizumab treatment for multiple sclerosis : updated recommendations for patient selection and monitoring. The Lancet neurology, Vol. 10, H. 8. pp. 745-758.

2008

Polman, C. and Kappos, L. and Freedman, M. S. and Edan, G. and Hartung, H. P. and Miller, D. H. and Montalbán, X. and Barkhof, F. and Selmaj, K. and Uitdehaag, B. M. and Dahms, S. and Bauer, L. and Pohl, C. and Sandbrink, R. and Benefit, investigators. (2008) Subgroups of the BENEFIT study : risk of developing MS and treatment effect of interferon beta-1b. Journal of neurology, Vol. 255, H. 4. pp. 480-487.

This list was generated on Sat Nov 23 04:30:29 2024 CET.